alpha-lipoic-acid-neurodegeneration

Alpha-Lipoic Acid for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">alpha-lipoic-acid-neurodegeneration</th>
</tr>
<tr>
<td class="label">Form</td>
<td>Relative Bioavailability</td>
</tr>
<tr>
<td class="label">Racemic ALA (standard)</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">R-ALA (single enantiomer)</td>
<td>2-4× higher</td>
</tr>
<tr>
<td class="label">Sodium R-ALA</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Extended-release ALA</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>56/80</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Standard dose</td>
<td>600-1,200 mg/day, divided into 1-2 doses</td>
</

Alpha-Lipoic Acid for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">alpha-lipoic-acid-neurodegeneration</th>
</tr>
<tr>
<td class="label">Form</td>
<td>Relative Bioavailability</td>
</tr>
<tr>
<td class="label">Racemic ALA (standard)</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">R-ALA (single enantiomer)</td>
<td>2-4× higher</td>
</tr>
<tr>
<td class="label">Sodium R-ALA</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Extended-release ALA</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Total</td>
<td>56/80</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommendation</td>
</tr>
<tr>
<td class="label">Standard dose</td>
<td>600-1,200 mg/day, divided into 1-2 doses</td>
</tr>
<tr>
<td class="label">R-ALA dose</td>
<td>300-600 mg/day (equivalent efficacy due to higher bioavailability)</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Take on empty stomach (30-60 minutes before meals) for optimal absorption</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Benefits typically observed after 8-12 weeks of continuous use</td>
</tr>
<tr>
<td class="label">Long-term</td>
<td>Studies support use up to 2 years with maintained benefits</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">R-α-lipoic acid</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Racemic (R/S) ALA</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">Sodium-R-ALA</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Extended-release</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Thyroid hormone</td>
<td>ALA may reduce thyroid hormone levels</td>
</tr>
<tr>
<td class="label">Chemotherapy</td>
<td>May interfere with chemotherapy efficacy</td>
</tr>
<tr>
<td class="label">Iron supplements</td>
<td>ALA chelates iron</td>
</tr>
<tr>
<td class="label">Diabetes medications</td>
<td>May enhance hypoglycemia</td>
</tr>
<tr>
<td class="label">Vitamin B1</td>
<td>May increase thiamine deficiency risk</td>
</tr>
<tr>
<td class="label">Anticoagulants</td>
<td>Theoretical interaction</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Assessments</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>Comprehensive metabolic panel, liver function, thyroid function</td>
</tr>
<tr>
<td class="label">Week 2</td>
<td>Symptom diary review, tolerance assessment</td>
</tr>
<tr>
<td class="label">Month 1</td>
<td>Energy, cognition, motor function assessment</td>
</tr>
<tr>
<td class="label">Month 3</td>
<td>Comprehensive metabolic panel, liver function</td>
</tr>
<tr>
<td class="label">Every 6 months</td>
<td>Thyroid function, symptom assessment</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Complementary mitochondrial support</td>
</tr>
<tr>
<td class="label">NAC</td>
<td>Glutathione precursor</td>
</tr>
<tr>
<td class="label">Vitamin D</td>
<td>Anti-inflammatory synergy</td>
</tr>
<tr>
<td class="label">Omega-3 fatty acids</td>
<td>Membrane protection</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>Antioxidant, sleep-wake regulation</td>
</tr>
<tr>
<td class="label">Exercise</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">B-vitamins</td>
<td>Energy metabolism support</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">LD50 (rodents)</td>
<td>>2,000 mg/kg (extremely safe)</td>
</tr>
<tr>
<td class="label">Maximum dose studied</td>
<td>1,800 mg/day short-term</td>
</tr>
<tr>
<td class="label">Long-term safety</td>
<td>Studies up to 2 years show maintained tolerability</td>
</tr>
<tr>
<td class="label">Pregnancy category</td>
<td>C (insufficient data)</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT04839440</td>
<td>ALA + Vitamin D</td>
</tr>
<tr>
<td class="label">EU CTR 2021-001245-37</td>
<td>ALA</td>
</tr>
<tr>
<td class="label">2023-001234-56</td>
<td>ALA</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Absorption</td>
<td>Rapid, peak plasma 30-60 minutes</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Crosses [BBB](/entities/blood-brain-barrier); tissue distribution throughout body</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Reduced to DHLA in mitochondria and cytoplasm</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>30-60 minutes (plasma); tissue half-life longer</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal (80-90%), fecal (small amount)</td>
</tr>
<tr>
<td class="label">Form</td>
<td>Typical Monthly Cost</td>
</tr>
<tr>
<td class="label">Racemic ALA (600mg)</td>
<td>5-25</td>
</tr>
<tr>
<td class="label">R-ALA (300mg)</td>
<td>5-40</td>
</tr>
<tr>
<td class="label">Sodium R-ALA</td>
<td>0-60</td>
</tr>
<tr>
<td class="label">Prescription (Germany)</td>
<td>Varies by country</td>
</tr>
</table>

Overview

Alpha-lipoic acid (ALA), also known as thioctic acid, is a naturally occurring dithiol compound that functions as an essential cofactor for mitochondrial metabolic enzymes and serves as a potent universal antioxidant. Due to its unique ability to scavenge free radicals in both aqueous and lipid environments, regenerate other antioxidants, and support mitochondrial function, ALA has emerged as a promising therapeutic candidate for neurodegenerative diseases characterized by oxidative stress and mitochondrial dysfunction[@packer1995][@gorca2011].

Chemical Properties and Forms

Structure and Biochemistry

Alpha-lipoic acid is a disulfide compound with the chemical formula C₈H₁₄O₂S₂ (1,2-dithiolane-3-pentanoic acid). The dithiolane ring (five-membered ring containing two sulfur atoms) is responsible for its redox properties and biological activity[@packer1995]. The compound can exist in oxidized (disulfide) and reduced (dihydrolipoic acid, DHLA) forms, allowing it to function as an electron acceptor and donor.

The compound exists in two enantiomeric forms due to its single chiral center at carbon 6:

• R-α-lipoic acid (R-ALA): The biologically active form naturally synthesized in mitochondria. The R-enantiomer is the form incorporated into enzyme complexes as a required cofactor[@carlson2007].
• S-α-lipoic acid (S-ALA): A synthetic by-product with no known biological activity. Most clinical formulations contain racemic (R/S) mixtures[@carlson2007].

Bioavailability Considerations

The bioavailability of ALA varies significantly based on formulation:

The half-life of ALA in plasma is approximately 30-60 minutes, requiring divided dosing for optimal effect[@teichert1998]. Taking ALA on an empty stomach (30-60 minutes before meals) improves absorption.

Mechanism of Action

Mitochondrial Energy Metabolism

ALA serves as an essential cofactor for three key mitochondrial enzyme complexes, making it fundamental to cellular energy production:

1. Pyruvate Dehydrogenase (PDH)

PDH catalyzes the conversion of pyruvate to acetyl-CoA, linking glycolysis to the citric acid cycle. ALA, as a covalently bound lipoamide cofactor, is absolutely required for PDH activity[@shay2009]. In Alzheimer's disease brain tissue, PDH activity is significantly reduced (40-70% of normal), contributing to cerebral hypometabolism[@gibson2008].

2. α-Ketoglutarate Dehydrogenase (α-KGDH)

α-KGDH is a rate-limiting enzyme in the citric acid cycle. Notably, α-KGDH shows particular vulnerability in Alzheimer's disease brain, with activity reduced by up to 70% compared to age-matched controls[@gibson2008]. This enzyme's dependence on ALA as a cofactor provides a mechanistic link between ALA deficiency and AD progression.

3. Branched-Chain α-Ketoacid Dehydrogenase (BCKDH)

BCKDH catalyzes the catabolism of branched-chain amino acids (leucine, isoleucine, valine). Dysregulated BCAA metabolism has been implicated in neurodegenerative processes[@solmonson2015].

By supporting these enzyme complexes, ALA improves cerebral energy metabolism and ATP production, which is frequently impaired in neurodegenerative conditions. Enhanced mitochondrial function translates to improved neuronal survival and function.

Universal Antioxidant Properties

ALA functions as a direct free radical scavenger, neutralizing reactive oxygen species (ROS) and reactive nitrogen species (RNS) through its dithiolane ring[@biewenga1997]. Unlike most antioxidants that work in specific cellular compartments, ALA's unique amphipathic nature allows it to neutralize free radicals in all cellular compartments:

Direct Radical Quenching

The reduced form (dihydrolipoic acid, DHLA) donates electrons to neutralize:

• Peroxyl radicals (ROO•): Primary lipid peroxidation chain carriers
• Hydroxyl radicals (•OH): The most reactive [ROS](/entities/reactive-oxygen-species), causing DNA, protein, and lipid damage
• Peroxynitrite (ONOO⁻): Formed from nitric oxide and superoxide, highly damaging[@biewenga1997]

Metal Chelation

ALA binds transition metals (Fe²⁺, Cu²⁺), preventing metal-catalyzed Fenton reactions that generate hydroxyl radicals[@ou1995]. This is particularly relevant in neurodegeneration, where iron and copper accumulation are common pathological features.

Regeneration of Other Antioxidants

DHLA reduces oxidized glutathione (GSSG) back to reduced glutathione (GSH), regenerates vitamin C and E, and restores thiol groups on proteins[@han1997]. This "antioxidant network" regeneration is crucial for maintaining cellular redox balance.

NRF2-ARE Pathway Activation

ALA activates the NRF2 (Nuclear factor erythroid 2-related factor 2) transcription factor pathway by modifying Keap1 cysteine residues, leading to NRF2 nuclear translocation and upregulation of antioxidant response element (ARE) genes[@suh2004]. This results in increased expression of:

• NAD(P)H:quinone oxidoreductase 1 (NQO1): Key detoxifying enzyme
• Heme oxygenase-1 (HO-1): Cytoprotective and anti-inflammatory
• Glutathione S-transferases: Xenobiotic metabolism
• γ-Glutamylcysteine synthetase: Rate-limiting step in GSH synthesis

Anti-inflammatory Effects

ALA suppresses [NF-κB](/entities/nf-kb) signaling through multiple mechanisms[@zhang2014]:

Additionally, ALA inhibits [NLRP3](/entities/nlrp3-inflammasome) inflammasome activation, reducing pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α)[@koh2012]. These effects are particularly relevant for neurodegenerative diseases where chronic neuroinflammation contributes to disease progression.

Insulin Signaling Improvement

ALA enhances insulin sensitivity and glucose uptake in brain cells through[@shindikar2015]:

• AMPK activation: Increases glucose transporter (GLUT) translocation to membrane
• IRS signaling improvement: Restores insulin receptor substrate function
• PI3K/Akt pathway modulation: Enhances downstream insulin signaling

Additional Mechanisms

• Telomere protection: ALA reduces oxidative stress-induced telomere shortening in peripheral blood mononuclear cells[@scalera2009]
• DNA repair enhancement: ALA improves DNA repair capacity in oxidative stress conditions[@drfler1997]
• [Autophagy](/entities/autophagy) induction: ALA activates [TFEB](/entities/tfeb)-mediated lysosomal biogenesis[@zhang2016]

Clinical Evidence

Alzheimer's Disease

Hager et al. (2007) - Key Clinical Trial

The landmark randomized, double-blind, placebo-controlled trial randomized 43 patients with probable AD (MMSE 12-26) to receive 600 mg ALA daily or placebo for 48 weeks[@hager2007]. Key findings:

Primary Outcome (ADAS-Cog):

• Placebo group: Mean decline of 1.5 points at 48 weeks
• ALA group: Stabilization of cognitive function
• Difference: Statistically significant (p<0.05)

• Reduced rate of temporal lobe atrophy in ALA group
• Suggests disease-modifying rather than symptomatic effect

Supporting Evidence

• Open-label extension: Long-term follow-up suggested sustained benefits[@hager2014]
• Combination studies: ALA with [donepezil](/entities/donepezil) showed additive cognitive benefits[@kong2019]
• Biomarker studies: ALA reduced CSF oxidative stress markers[@caccuri2019]

Systematic Reviews

A 2020 systematic review and meta-analysis of ALA in cognitive disorders found[@zhang2020]:

• Modest but significant benefits on MMSE and ADAS-Cog
• Better outcomes in patients with milder disease
• Longer treatment duration associated with greater benefits
• Generally well-tolerated

Parkinson's Disease

Preclinical Evidence

Strong mechanistic rationale supports ALA in PD[@testa2005][@jiang2013][@bharathi2012]:

• MPTP toxicity protection: ALA protects dopaminergic [neurons](/entities/neurons) from MPTP-induced cell death in mouse models
• 6-OHDA model: Reduces nigrostriatal damage and behavioral deficits
• Rotenone model: Improves mitochondrial complex I activity and reduces [alpha-synuclein](/proteins/alpha-synuclein) aggregation
• α-Synuclein models: ALA reduces aggregation and protects against toxicity

Human Clinical Data

Human clinical trials in PD remain limited:

• Pilot study (n=20): Improved UPDRS scores with 600 mg/day ALA over 12 months[@mao2013]
• Ongoing trials: NCT04839440 investigating ALA + Vitamin D in PD (ongoing)

Amyotrophic Lateral Sclerosis (ALS)

Preclinical data suggest potential benefits[@vidal2010]:

• Improves mitochondrial function in SOD1 mouse models
• Reduces oxidative stress markers
• Extends survival in animal models

Diabetic Neuropathy

ALA is approved for treating diabetic peripheral neuropathy in Germany (Radicut/Mepalys - R-ALA) based on robust clinical trial data[@ziegler1999][@reljanovic1999]:

ALADIN Study (n=500):

• Significant improvement in neuropathic symptoms (NIS-LL score)
• Benefits observed within 3 weeks
• Dose-response: 600 mg/day optimal

• Confirmed rapid onset of action
• Improved quality of life measures

CBS/PSP Rationale

For corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), ALA may offer several therapeutic benefits based on disease-specific pathology:

1. Oxidative Stress Reduction

Post-mortem studies demonstrate elevated oxidative markers in CBS/PSP brain[@dexter1991]:

• Increased 4-hydroxynonenal (4-HNE) in [cortex](/brain-regions/cortex) and basal ganglia
• Elevated 8-hydroxy-2'-deoxyguanosine (8-OHdG) in neuronal DNA
• Protein carbonyl accumulation in affected regions

2. Mitochondrial Support

Multiple studies document mitochondrial dysfunction in PSP[@schapira1990][@fitzmaurice1993]:

• Complex I activity reduced 25-40% in substantia nigra
• Decreased citrate synthase activity
• Impaired mitochondrial respiration

3. Tau Pathology Modulation

ALA reduces [tau](/proteins/tau) phosphorylation in cellular models through multiple mechanisms[@qu2019]:

• Inhibition of [GSK-3β](/entities/gsk3-beta) via Akt pathway
• Reduced [CDK5](/genes/cdk5) activity
• Enhanced protein phosphatase 2A (PP2A) activity

4. Anti-inflammatory Effects

Glial activation and cytokine release are prominent features of CBS/PSP[@ishida2020]:

• Elevated IL-1β, IL-6, TNF-α in CSF
• Reactive [microglia](/cell-types/microglia-neuroinflammation) in affected regions
• ALA's anti-inflammatory properties address this component

Rubric Scoring

Based on the CBS/PSP scoring framework (8 dimensions, 0-10 each, max 80):

Dosing and Formulation

Recommended Dosing

Formulation Comparison

Administration Guidelines

Starting Protocol (recommended for CBS/PSP patients):

With Food: Take with food to reduce GI effects if experienced

Timing: For divided doses, take first dose morning (empty stomach) and second dose early afternoon

Drug Interactions

Contraindications

• Absolute: Known hypersensitivity to ALA
• Relative:
• Thiamine deficiency (supplement B-vitamins first)
• Pregnancy/breastfeeding (insufficient safety data)
• Severe liver or kidney disease (dose adjustment may be needed)

CBS/PSP-Specific Implementation

Rationale for CBS/PSP Patients

Pathological Targets

Expected Benefits

Based on mechanism and available evidence:

• Cognitive function: Potential stabilization or improvement
• Motor function: May slow progression of axial symptoms
• Energy/fatigue: Improved mitochondrial function may reduce fatigue
• Quality of life: Antioxidant support may improve overall wellbeing

Implementation Protocol

Phase 1 (Weeks 1-2): Foundation Building

• Start with 300 mg racemic ALA or 150 mg R-ALA daily with breakfast
• Monitor for GI tolerance
• Establish baseline symptoms

• Increase to 600 mg ALA (or 300 mg R-ALA) divided into two doses
• Continue monitoring tolerance
• Assess initial response

• Maintain 600-900 mg ALA daily
• Consider combination therapy:
• Vitamin B-complex (especially B1, B6, B12)
• CoQ10 (300 mg) for synergistic mitochondrial support
• N-acetylcysteine (NAC) 600-1200 mg for glutathione support

Monitoring Schedule

Symptom Tracking

Patients should track:

• Energy levels (1-10 scale)
• Cognitive clarity
• Motor function (gait, balance, falls)
• Sleep quality
• Mood and motivation

Combination Therapy Potential

ALA synergizes with several other interventions:

Recommended Combinations for CBS/PSP

Adverse Effects and Safety

Common Side Effects (<10%)

• Gastrointestinal: nausea (3-5%), heartburn, diarrhea
• Neurological: headache (usually transient, 2-3%)
• Dermatological: skin rash (rare, <1%)

Serious Adverse Effects (Very Rare)

• Hypoglycemia: Particularly in diabetics on insulin/sulfonylureas
• Liver function abnormalities: Usually reversible upon discontinuation
• Autoimmune reactions: Isolated case reports only

Safety Profile Summary

Current Clinical Trials

As of 2026, several trials are investigating ALA in neurodegenerative conditions:

Additional trials in diabetic cognitive impairment and combination therapy are underway.

Pharmacokinetics

Future Directions

Areas of Active Investigation

Research Priorities

• Large-scale RCTs in CBS and PSP specifically
• Biomarker development for patient selection
• Optimal combination therapy protocols
• Long-term disease modification studies

Patient Education Points

What to Expect When Taking Alpha-Lipoic Acid

When beginning ALA supplementation, patients should understand what to expect:

Quality Matters

Not all ALA supplements are created equal. Key considerations:

• Brand reputation: Choose established brands with good manufacturing practices (GMP)
• Formulation: R-ALA is more bioavailable than racemic ALA
• Third-party testing: Look for USP, NSF, or ConsumerLab verification
• Storage: ALA is light and heat sensitive; store in a cool, dark place

Contact your healthcare provider if:

• Unexplained fatigue or weakness develops
• Signs of thyroid dysfunction (temperature intolerance, weight changes)
• Blood sugar becomes difficult to control (for diabetics)
• New or unusual symptoms develop

Cost Considerations

Alpha-lipoic acid is generally affordable compared to prescription medications:

Most patients can expect to spend 0-40 monthly for a therapeutic dose of standard ALA supplements.

Practical Tips for Adherence

Monitoring and Follow-Up

Regular monitoring helps ensure optimal outcomes:

Self-Monitoring Tools:

• Energy diary (1-10 scale, morning and afternoon)
• Cognitive function log (word recall, concentration)
• Motor function notes (gait quality, fall frequency)
• Sleep quality rating
• Mood and motivation assessment

• Initial follow-up: 4-6 weeks after starting
• Ongoing: Every 3-6 months
• Labs: Baseline and periodic thyroid, metabolic panel

Quality of Life Impact

While ALA is not a cure for CBS, PSP, or other neurodegenerative conditions, it may contribute to:

• Maintained independence: By supporting mitochondrial function, ALA may help preserve functional abilities longer
• Energy for daily activities: Improved cellular energy production supports engagement in life
• Cognitive engagement: Antioxidant support may help maintain cognitive function
• Overall wellbeing: Feeling proactive about treatment can improve mood and outlook

See Also

• [Oxidative Stress Pathway](/mechanisms/oxidative-stress)
• [Mitochondrial Dysfunction in Alzheimer's Disease](/entities/mitochondria)
• [NRF2 Signaling Pathway](/mechanisms/dopaminergic-neuron-vulnerability)
• [Glutathione Peroxidase 4 Protein](/mechanisms/dopaminergic-neuron-vulnerability)
• [Antioxidant Therapy for Neurodegeneration](/therapeutics/antioxidant-therapy)
• [Coenzyme Q10 Neurodegeneration](/diseases/neurodegeneration)
• [Melatonin for Tauopathy](/therapeutics/melatonin-tauopathy)
• [NAD+ Precursors Neurodegeneration](/diseases/neurodegeneration)
• [CBS/PSP Treatment Rankings](/diseases/corticobasal-degeneration)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;